Human-Bovine Chimeric Respiratory Syncytial Virus (RSV) Vaccines

Available for licensing and commercial development is a patent estate and related biological materials for making human-bovine chimeric virus particles for formulating live attenuated vaccines against human respiratory syncytial virus (RSV). Chimeric human-bovine RSVs are recombinantly engineered to incorporate nucleotide sequences from both human and bovine RSV strains and produce infectious, chimeric viruses that elicit anti-RSV immunological responses in humans and non-human primates. The chimeras incorporate partial or complete human or bovine RSV background genomes with one or more recombinantly integrated heterologous genes or genome segments of a different RSV strain.

Heterologous genes of interest for making chimeric recombinants include NS1, NS2, N, P, M, SH glycoprotein (or an immunogenic domain or epitope thereof), M2(ORF1), M2(ORF2), L, F or G genes or a genome segment including a protein or portion thereof or alternatively a leader, trailer or intergenic region of the RSV genome, or a segment thereof. A variety of additional mutations and nucleotide modifications are provided within the human-bovine chimeric RSV of the invention to yield desired phenotypic and structural effects. Exemplary human-bovine chimeric RSV of the invention incorporate a chimeric RSV genome or antigenome comprising both human and bovine polynucleotide sequences, as well as a major nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P), a large polymerase protein (L), and a RNA polymerase elongation factor. Additional RSV proteins may be included in various combinations to provide a range of infectious subviral particles up to a complete viral particle or a viral particle containing supernumerary proteins, antigenic determinants or other additional components.

Potential Commercial Applications: Competitive Advantages:
  • Infectious Disease - Respiratory Syncytial Virus
  • Vaccines
  • Therapeutics
  • Prophylactics
  • Childhood Vaccines


Ursula Buchholz
Peter Collins (NIAID)  ➽ more inventions...

Brian Murphy (NIAID)  ➽ more inventions...

Stephen Whitehead (NIAID)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 00810119.1 issued 2007-12-12
U.S. Pat: 784216 issued 2006-06-08
U.S. Pat: 1287152 issued 2008-12-31
U.S. Pat: 147447 issued 2010-09-01
U.S. Pat: 10-0905450 issued 2009-06-24
U.S. Pat: 7,829,102 issued 2010-11-09
U.S. Pat: 7,842,798 issued 2010-11-30
U.S. Pat: 7,820,182 issued 2010-10-26
MX Application No. 2002-000220
BR Application No. PI0013195-4
CN Application No. 200710167112.6
US Application No. 11/097,946
US Application No. 11/203,620
US Application No. 10/704,116
US Application No. 60/143,132
US Application No. 09/602,212
US Application No. 10/030,951
US Application No. 10/899,626
US Application No. 11/033,996


UJ Buchholz et al. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine. J Virol. 2000 Feb;74(3):1187-1199.

PubMed abs

A Karger et al. Recombinant bovine respiratory syncytial virus with deletions of the G or SH genes: G and F proteins bind heparin. J Gen Virol. 2001 Mar;82(Pt 3):631-640.

PubMed abs

UJ Buchholz et al. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol. 1999 Jan;73(1):251-259.

PubMed abs

Collaboration Opportunity:

The NIAID Office of Technology Development is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize attenuated live vaccines against respiratory syncytial virus (RSV). Please contact Barry Buchbinder at 301-594-1696 for more information.

Licensing Contact:
Admin. Licensing Specialist (ALS),

OTT Reference No: E-178-1999-0
Updated: Sep 1, 2008